Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 3/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10015874 | 0.66 | RAD52 (0.32) | — | |
| SCHEMBL498978 | 0.65 | BACE1 (0.36) | KDM4EPOLB | |
| SCHEMBL11745515 | 0.61 | CYP4A11 (0.47) | HIF1AHTT | |
| SCHEMBL10122677 | 0.60 | HRH4 (0.59) | KDM4EPOLBDAO | |
| SCHEMBL6055110 | 0.59 | GABRA1 (0.45) | HIF1AKDM4EPOLB | |
| SCHEMBL1999843 | 0.58 | — | — | |
| SCHEMBL24074795 | 0.58 | UCHL3 (0.44) | HTT | |
| SCHEMBL9340223 | 0.57 | PTGS2 (0.47) | — | |
| SCHEMBL2495804 | 0.57 | — | — | |
| SCHEMBL13187466 | 0.57 | DAO (0.36) | KDM4EPOLBDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106089-B2 | Reacting pyrrolylalkylcarbinole, furanylalkylcarbinole or thiophenylalkylcarbinole units; cyclodehydration, hydroboration, oxidation, palladium-catalyzed Suzuki-Miyaura cross-coupling; anticarcinogenic agents, antitumor, and antiproliferative agents; autoimmune and neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE (FR) | 2012-01-31 | — | — | US | disclosed |
| US-8106089-B2 | Reacting pyrrolylalkylcarbinole, furanylalkylcarbinole or thiophenylalkylcarbinole units; cyclodehydration, hydroboration, oxidation, palladium-catalyzed Suzuki-Miyaura cross-coupling; anticarcinogenic agents, antitumor, and antiproliferative agents; autoimmune and neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE (FR) | 2012-01-31 | — | — | US | disclosed |
| US-8106089-B2 | Reacting pyrrolylalkylcarbinole, furanylalkylcarbinole or thiophenylalkylcarbinole units; cyclodehydration, hydroboration, oxidation, palladium-catalyzed Suzuki-Miyaura cross-coupling; anticarcinogenic agents, antitumor, and antiproliferative agents; autoimmune and neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE (FR) | 2012-01-31 | — | — | US | disclosed |
| US-20080275103-A1 | Anti-Tubulin Acting Arylpyrrol, Arylfuran And Arylthiophene Derivatives, Method For The Preparation Thereof And For The Use Thereof As An Antimitotic | UNIVERSITE DE RENNES (FR) | 2008-11-06 | — | — | US | disclosed |
| US-20080275103-A1 | Anti-Tubulin Acting Arylpyrrol, Arylfuran And Arylthiophene Derivatives, Method For The Preparation Thereof And For The Use Thereof As An Antimitotic | UNIVERSITE DE RENNES (FR) | 2008-11-06 | — | — | US | disclosed |
| US-20080275103-A1 | Anti-Tubulin Acting Arylpyrrol, Arylfuran And Arylthiophene Derivatives, Method For The Preparation Thereof And For The Use Thereof As An Antimitotic | UNIVERSITE DE RENNES (FR) | 2008-11-06 | — | — | US | disclosed |
| EP-1751100-B1 | ANTI-TUBULIN ACTING ARYLPYRROL, ARYLFULRAN AND ARYLTHIOPENE DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF AS AN ANTIMITOTIC | CENTRE NAT RECH SCIENT (FR) | 2008-01-09 | — | — | EP | disclosed |
| EP-1751100-B1 | ANTI-TUBULIN ACTING ARYLPYRROL, ARYLFULRAN AND ARYLTHIOPENE DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF AS AN ANTIMITOTIC | CENTRE NAT RECH SCIENT (FR) | 2008-01-09 | — | — | EP | disclosed |
| EP-1751100-A1 | ANTI-TUBULIN ACTING ARYLPYRROL, ARYLFULRAN AND ARYLTHIOPENE DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF AS AN ANTIMITOTIC | Centre National de la Recherche Scientifique (CNRS) (FR) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005115979-A1 | ANTI-TUBULIN ACTING ARYLPYRROL, ARYLFULRAN AND ARYLTHIOPENE DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF AS AN ANTIMITOTIC | CENTRE NATIONAL DE LA RECHERCHE SCIENTIQUE (CNRS) (FR) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275103-A1 | Anti-Tubulin Acting Arylpyrrol, Arylfuran And Arylthiophene Derivatives, Method For The Preparation Thereof And For The Use Thereof As An Antimitotic | TUBB1, TUBB3, TUBB | HIF1A 4577/4885EPAS1 4790/4885KDM4E 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.